Skip to main content

Table 1 The basic information and data of all included studies in the meta-analysis

From: Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis

AuthorYearCountryNo. of patientsSex (M/F)Tumor typeAge (years)
Median (range)
Cut-off valueSurvival analysisTreatmentNOS score
Kim2015Korea277218/59UTUC63.7 (29.5–90)150CSS, DFSNUx7
Zhang2015China124100/24BC65 (30–78)140OSRC8
Song2016China14086/54UTUC67 (39–81)128DFS, PFSRNU6
Altan2017Turkey11386/27UTUC63.7150DFS, PFSRNU7
Dalpiaz2017Austria180109/71UTUC70150OS, PFSRNU8
Huang2017China481311/170UTUC65 (30–89)241OS, PFSRNU7
Kang2017Korea15511302/249BC65 (57–72)124OS, CSSTURB7
Mao2017China207169/38BC66 (59–80)123DFS, PFSTURB8
Miyake2017Japan11795/22BC72150OS, CSSRC8
Rajwa2018Poland144NABCNA161OS, CSSRC6
Son2018Korea1137825/312UTUC69142DFS, PFSRNU6
Itami2019Japan12596/29UTUC72 (38–90)150OS, DFSNUx7
Kuroda2019Japan187138/49UTUC71 (38–90)165DFS, PFSRNU7
Yuk2019Korea385327/58BC72.6171OS, CSSTURB7
Zhu2019China186157/29BC65111OSRC7
  1. OS overall survival, DFS disease-free survival, PFS progression-free survival, CSS cancer-specific survival, NUx nephroureterectomy, RC radical cystectomy, RNU radical nephroureterectomy, TURB transurethral resection of bladder tumor, NA not available, NOS Newcastle–Ottawa Scale, UTUC upper tract urothelial carcinoma, BC bladder cancer